期刊
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
卷 12, 期 12, 页码 2220-2230出版社
AMER SCIENTIFIC PUBLISHERS
DOI: 10.1166/jbn.2016.2313
关键词
Parkinson's Disease (PD); Blood-Brain Barrier (BBB); Intranasal; Glial Cell-Derived Neurotrophic Factor (GDNF); Nanostructured Lipid Carriers (NLC)
资金
- Ministerio de Economia y Competitividad [SAF2013-42347-R]
- University of the Basque Country (UPV/EHU) [UFI 11/32]
- Basque Government [Saiotek S-PE13UN048, GIC IT 794/13]
- FEDER funds
- University of the Basque Country
Parkinson's disease (PD) is the second most frequent neurodegenerative disorder, but current therapies are only symptomatic. A promising alternative to address the neurodegenerative process is the use of neurotrophic factors, such as the glial cell-derived neurotrophic factor (GDNF). However, its clinical use has been limited due to its short half-life and rapid degradation after in vivo administration, in addition to difficulties in crossing the blood-brain barrier (BBB). This barrier is a limiting factor in brain drug development, making the future progression of neurotherapeutics difficult. In the past few years, intranasal drug delivery has appeared as an alternative non-invasive administration route to bypass the BBB and target drugs directly to the CNS. Thus, the aim of this work was to study the in vivo neuroprotective effect of intranasally administered GDNF, encapsulated in chitosan-coated nanostructured lipid carrier (CS-NLC-GDNF), in a 6-OHDA partially lesioned rat model. The developed CS-NLC-GDNF showed a particle size of approximately 130 nm and high encapsulation efficiency. The in vitro study in PC-12 cells demonstrated the ability of the encapsulated GDNF to protect these cells against 6-OHDA toxin. After two weeks of daily intranasal administration of treatments, the administration of CS-NLC-GDNF achieved a behavioral improvement in rats, as well as a significant improvement in both the density of TH+ fibres in the striatum and the TH+ neuronal density in the SN. Thus, it can be concluded that the nose-to-brain delivery of CS-NLC-GDNF could be a promising therapy for the treatment of PD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据